<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256853</url>
  </required_header>
  <id_info>
    <org_study_id>VAC002</org_study_id>
    <nct_id>NCT01256853</nct_id>
  </id_info>
  <brief_title>Modified Vaccinia Ankara (MVA) Vaccine Study</brief_title>
  <official_title>A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, dose escalation trial of MVA-EBNA1/LMP2 vaccine across a pre-defined range&#xD;
      of doses in patients in remission having had an EBV+ nasopharyngeal carcinoma (NPC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine safety and to characterise the toxicity profile of MVA-EBNA1/LMP2 vaccine</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe changes in the frequency of functional T-cell responses to MHC class I and II-restricted epitopes within EBNA1 and LMP2 in peripheral blood at sequential time-points before, during and up to nine months after the vaccination course.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in levels of EBV genome levels in plasma</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <condition>Epstein-Barr Virus Infections</condition>
  <arm_group>
    <arm_group_label>MVA Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVA Vaccine</intervention_name>
    <description>The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.</description>
    <arm_group_label>MVA Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed NPC, in which the presence of EBV within the malignant cells&#xD;
             has been demonstrated by (1) EBER (EBV early RNA) in situ hybridisation in more than&#xD;
             50% of the malignant cells, or (2) undifferentiated or poorly differentiated carcinoma&#xD;
             histology in association with a raised serum titer of IgA to EBV VCA.&#xD;
&#xD;
          -  Patients in remission from disease, ie complete response (CR) or unconfirmed complete&#xD;
             response (CRu).&#xD;
&#xD;
          -  Completion of standard therapy for malignancy at least 12 weeks before trial entry.&#xD;
&#xD;
          -  Written informed consent and the ability of the patient to co-operate with treatment&#xD;
             and follow up must be ensured and documented.&#xD;
&#xD;
          -  Age greater than 18 years.&#xD;
&#xD;
          -  World Health Organisation (WHO) performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 4 months.&#xD;
&#xD;
          -  Haematological and biochemical indices (these measurements must be performed within 28&#xD;
             days prior to the patient going on study):&#xD;
&#xD;
               -  Haemoglobin (Hb) &gt; 10.0 g/dl&#xD;
&#xD;
               -  Lymphocytes &gt; 1.0 x 109/L (or above the lower limit of normal range of&#xD;
                  institutional laboratory)&#xD;
&#xD;
               -  Neutrophils ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelets (Plts) ≥ 100 x 109/L&#xD;
&#xD;
               -  baseline liver function tests :&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x upper normal limit&#xD;
&#xD;
               -  Serum alkaline phosphatase, alanine amino-transferase (ALT) and/or aspartate&#xD;
                  amino-transferase (AST) &lt; 1.5 x ULN.&#xD;
&#xD;
               -  baseline renal function test:&#xD;
&#xD;
               -  calculated creatinine clearance &gt; 50ml/min Female patients of child-bearing&#xD;
                  potential are eligible, provided they have a negative pregnancy test prior to&#xD;
                  enrolment and agree to use appropriate medically approved contraception during&#xD;
                  the study up to six months after the last vaccination.&#xD;
&#xD;
          -  Male patients must agree to use appropriate medically approved contraception during&#xD;
             the study up to six months after the last vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving current chemotherapy or radiotherapy, or received within 12 weeks of trial&#xD;
             entry.&#xD;
&#xD;
          -  Known chronic active infection with Hepatitis B, Hepatitis C or Human Immunodeficiency&#xD;
             Virus (HIV).&#xD;
&#xD;
          -  Current active autoimmune disease.&#xD;
&#xD;
          -  Current active skin diseases requiring therapy (psoriasis, eczema etc).&#xD;
&#xD;
          -  Ongoing active infection.&#xD;
&#xD;
          -  History of anaphylaxis or severe allergy to vaccination.&#xD;
&#xD;
          -  Allergy to eggs or egg products.&#xD;
&#xD;
          -  Previous myeloablative therapy followed by an autologous or allogeneic haematopoietic&#xD;
             stem cell transplant.&#xD;
&#xD;
          -  Patients who have had a splenectomy or splenic irradiation, or with known splenic&#xD;
             dysfunction.&#xD;
&#xD;
          -  Receiving current immunosuppressive medication, including corticosteroids.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Ongoing toxic manifestations of previous treatment. Exceptions to this are alopecia or&#xD;
             certain Grade 1 toxicities which in the opinion of the Investigator and Cancer&#xD;
             Research UK should not exclude the patient.&#xD;
&#xD;
          -  Major thoracic and/or abdominal surgery in the preceding four weeks from which the&#xD;
             patient has not yet recovered.&#xD;
&#xD;
          -  Patients with any other condition which in the Investigator's opinion would not make&#xD;
             the patient a good candidate for the clinical trial.&#xD;
&#xD;
          -  Concurrent congestive heart failure or prior history of class III/ IV cardiac disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony TC Chan, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>December 21, 2011</last_update_submitted>
  <last_update_submitted_qc>December 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <keyword>histologically confirmed EBV+ NPC patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

